Etiology In Wuhan Research Articles

Personal Protective Equipment used in Coronavirus Pandemic

Cases of pneumonia of unknown etiology in Wuhan, China's Hubei province, was reported to the China country Office of the World Health Organization (WHO) on December 31, 2019. The causative agent was identified as a new coronavirus (2019-nCoV) on January 7, 2020, and the causative agent was identified as a new coronavirus (2019-nCoV) that has not previously been detected in humans. Later, the name of the 2019-nCoV disease was accepted as COVID-19, and the virus was named as SARS-CoV-2 due to its similarity to SARS CoV.1-3 During the SARS-CoV-2 pandemic period, special attention should be paid to personal protective equipment (PPE). Medical staff protection is particularly important because of the risk of infecting other medical team members, not only doctors, nurses, or paramedics but also other support staff necessary to ensure continuity of care for patients.

Improved Molecular Diagnosis of COVID-19 by the Novel, Highly Sensitive and Specific COVID-19-RdRp/Hel Real-Time Reverse Transcription-PCR Assay Validated In Vitro and with Clinical Specimens.

On 31 December 2019, the World Health Organization was informed of a cluster of cases of pneumonia of unknown etiology in Wuhan, China. Subsequent investigations identified a novel coronavirus, now named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), from the affected patients. Highly sensitive and specific laboratory diagnostics are important for controlling the rapidly evolving SARS-CoV-2-associated coronavirus disease 2019 (COVID-19) epidemic. In this study, we developed and compared the performance of three novel real-time reverse transcription-PCR (RT-PCR) assays targeting the RNA-dependent RNA polymerase (RdRp)/helicase (Hel), spike (S), and nucleocapsid (N) genes of SARS-CoV-2 with that of the reported RdRp-P2 assay, which is used in >30 European laboratories. Among the three novel assays, the COVID-19-RdRp/Hel assay had the lowest limit of detection in vitro (1.8 50% tissue culture infective doses [TCID50]/ml with genomic RNA and 11.2 RNA copies/reaction with in vitro RNA transcripts). Among 273 specimens from 15 patients with laboratory-confirmed COVID-19 in Hong Kong, 77 (28.2%) were positive by both the COVID-19-RdRp/Hel and RdRp-P2 assays. The COVID-19-RdRp/Hel assay was positive for an additional 42 RdRp-P2-negative specimens (119/273 [43.6%] versus 77/273 [28.2%]; P < 0.001), including 29/120 (24.2%) respiratory tract specimens and 13/153 (8.5%) non-respiratory tract specimens. The mean viral load of these specimens was 3.21 × 104 RNA copies/ml (range, 2.21 × 102 to 4.71 × 105 RNA copies/ml). The COVID-19-RdRp/Hel assay did not cross-react with other human-pathogenic coronaviruses and respiratory pathogens in cell culture and clinical specimens, whereas the RdRp-P2 assay cross-reacted with SARS-CoV in cell culture. The highly sensitive and specific COVID-19-RdRp/Hel assay may help to improve the laboratory diagnosis of COVID-19.

Perspectives from the Cancer and Aging Research Group: Caring for the vulnerable older patient with cancer and their caregivers during the COVID-19 crisis in the United States

In December 2019, a cluster of patients was admitted with the diagnosis of pneumonia of unknown etiology in Wuhan, China [1]. The number of cases rapidly increased to 7734 in Wuhan and new cases were found in other countries such as Taiwan and Thailand by January 30, 2020 [2]. On the same day, the World Health Organization declared the outbreak as a Public Health Emergency of International Concern. By April 11, 2020, more than 1.5 million people were diagnosed with coronavirus disease 2019 (COVID-19) and over 90,000 died [3].

SARS-CoV-2 / 2019-Novel Corona Virus: An Epidemic to Pandemic

An unexpected outbreak of pneumonia of unfamiliar aetiology in Wuhan,Hubei, China was reported in December 2019. World Health Organization identified the pathogen and named it COVID-19. COVID-19 madethe world go through a cisis. The impact of this viral disease is now an issue of major concern. Respiratory infections, dry cough with fever are the major symptoms which are due to beta coronavirus, namely Severe Acute Respiratory Syndrome corona virus 2 (SARS-CoV-2). Within a short spell, COVID-19 spread all over China. Since January to today 24 March 2020 this epidemic turned into pandemic with continuous rise of cases and deaths. Italy, Germany, Spain, USA, Iran, France are the countries where the disease is spreading in a community level and rest of the countries over the globe the positive cases are also comingin. As the disease is communicable, it is highly necessary to take measures before it starts spreading in countries like India where the population is very high. The treatment of this severe acute respiratory syndrome corona virus 2 is not clear so far. Prevention is the only way to stop spreading this fatal disease. In view of this, the total state of knowledge regarding COVID-19 and the suggestive prevention are discussed by considering countries (considering India) where the population is high and this pandemic has just started spreading.

Coronavirus disease COVID-2019

The paper presents data on the coronavirus disease COVID-2019 caused by the SARS-CoV-2 coronavirus, which was temporarily named 2019-nCoV (2019 novel coronavirus) until 11 February 2020. An outbreak of pneumonia of unknown etiology in Wuhan ( Hubei province of China ) which was first described in an official publication of the Chinese Office of the World Health Organization on December 31, 2019, attracted attention of both dedicated experts and the entire international community. On January 30, 2019 it was recognised as a public health emergency of international concern. The first cases were reported on December 12, 2019 in China, and on January 31, 2020 Russia reported its first two cases of the infection in two Chinese citizens staying in Russia. The causative agent is the new SARS-CoV-2 coronavirus. It had not been detected before, and was first identified by Chinese researchers on January 7, 2020 under the temporary name 2019-nCoV. The aim of the study was to summarise information about coronavirus disease COVID-2019 beginning from the onset of the epidemic until early March 2020. The paper provides general information about coronaviruses, developments of the COVID-2019 epidemic caused by the SARS-CoV-2 coronavirus, and gives an assessment of the global epidemiological situation. It cites the recommendations of national regulatory authorities and the World Health Organization on the treatment of various forms of coronavirus infection and septic shock caused by SARS-CoV-2, including target values of systemic hemodynamics, a list of recommended medicines, methods of their use, and limitations of pharmacotherapy.

Outbreak of pneumonia of unknown etiology in Wuhan, China: The mystery and the miracle.

Outbreak of pneumonia of unknown etiology in Wuhan, China: The mystery and the miracle.

Pneumonia of unknown aetiology in Wuhan, China: potential for international spread via commercial air travel.

There is currently an outbreak of pneumonia of unknown aetiology in Wuhan, China. Although there are still several unanswered questions about this infection, we evaluate the potential for international dissemination of this disease via commercial air travel should the outbreak continue.

Hypertension in the Era of COVID-19 Pandemic: a Mini Review

On December 31st, 2019, several cases of pneumonia of unknown etiology in Wuhan, Hubei province, China were reported to the World Health Organization and they were linked to Huan Seafood Wholesale Market.

Cervical cancer vaccine may come soon to Canada

In late December 2019, Chinese authorities reported a cluster of pneumonia cases of unknown aetiology in Wuhan, China¹. A novel strain of coronavirus named Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was isolated and identified on 2 January 2020 ². Human-to-human transmission have been confirmed by a study of a family cluster and have occurred in health-care workers ^3,4. Until 10 February 2020, 42638 cases of 2019 novel coronavirus disease (COVID-19) have been confirmed in China, of which 31728 came from Hubei Province (Figure). Wenzhou, as a southeast coastal city with the most cases outside Hubei Province, its policy control and epidemic projections have certain references for national and worldwide epidemic prevention and control. We described the epidemiologic characteristics of COVID-19 in Wenzhou and made a transmission model to predict the expected number of cases in the coming days.